Clinical trials: Non-Myeloid Malignancy
Chemotherapy-Induced Neutropenia
Safety and Efficacy Trial of Recombinant Human Granulocyte Colony Stimulating Factor (GCSF)
A Phase III Randomized Controlled Open Label Comparative Multicentric Trial To Compare The Safety And Efficacy of Indigenous Recombinant Human Granulocyte Colony Stimulating Factor (rhG-CSF) With Neupogen In Patients on…
- Trial name
- NCT00776165
- Testing
- Recombinant Human GCSF (Shantha Biotechnics Limited), Neupogen
- Where
- 7 sites in India
- Volunteers
- 126 people
- Sponsor
- Shantha Biotechnics Limited
T Cell Lymphoma, B Cell Lymphoma
A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed/Refractory Hematologic Malignancies
This is an open label, multicenter, phase 1/2 dose evaluation and cohort expansion study evaluating the safety and efficacy of CTX131 in subjects with Relapsed/Refractory Hematologic Malignancies
- Conditions
- T Cell Lymphoma, B Cell Lymphoma, Acute Myeloid Leukemia
- Trial name
- NCT06492304
- Testing
- CTX131
- Where
- 7 sites in United States, Australia
- Volunteers
- 12 people
- Sponsor
- CRISPR Therapeutics
Leukemia, Myeloid, Acute
A Study of Cusatuzumab Plus Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia Who Are Not Candidates for Intensive Chemotherapy
The purpose of this study is to determine the efficacy of cusatuzumab in combination with azacitidine in participants with previously untreated acute myeloid leukemia (AML) who are not eligible for intensive chemotherapy.
- Trial name
- CULMINATE (NCT04023526)
- Testing
- Azacitidine, Cusatuzumab
- Where
- 56 sites in Australia, Brazil and 7 more
- Volunteers
- 103 people
- Sponsor
- OncoVerity, Inc.
Acute Myeloid Leukemia (AML)
Ivosidenib (TIBSOVO®) Combined With Azacitidine According to Current SmPC
The goal of this non-interventional study is to evaluate quality of life (QoL) in adult patients with newly diagnosed IDH1 R132-mutated AML who are not eligible to receive standard induction chemotherapy and who are treated with…
- Trial name
- CONFIDHENCE (NCT06181734)
- Testing
- Ivosidenib
- Where
- Germany
- Volunteers
- 8 people
- Sponsor
- iOMEDICO AG
Leukemia, Myeloid, Acute, Myelodysplastic Syndromes
An Efficacy and Safety Study of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Adults With Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly Patients With Acute Myeloid Leukemia (AML)
The primary objective of this study is to evaluate the efficacy of subcutaneous azacitidine in combination with durvalumab as compared with subcutaneous azacitidine alone in adults with previously untreated, higher risk MDS who…
- Trial name
- NCT02775903
- Testing
- Azacitidine, Durvalumab
- Where
- 103 sites in United States, Austria and 10 more
- Volunteers
- 213 people
- Sponsor
- Celgene
Acute Myelocytic Leukemia, Acute Lymphocytic Leukemia
Safety and Tolerability of HSC835 in Patients With Hematological Malignancies
This study evaluated the safety and tolerability of using HSC835 in patients with hematological malignancies.
- Conditions
- Acute Myelocytic Leukemia, Acute Lymphocytic Leukemia, Chronic Myelogenous Leukemia, Myelodysplastic Syndrome
- Trial name
- NCT01474681
- Testing
- HSC835
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Novartis Pharmaceuticals
NHL, Adult, AML, Adult Recurrent
A Phase I Study of Euthare-155008(ETH-155008) in AML and NHL Patients
This Trial is an open-label, multicenter trial to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of ETH-155008 in subjects with AML and NHL who previously received standard treatment or are…
- Trial name
- NCT05758610
- Testing
- ETH-155008
- Where
- 2 sites in China
- Volunteers
- 60 people
- Sponsor
- Shengke Pharmaceuticals (Jiangsu) Limited, China
Neoplasms, Anemia
Treatment for Anemic Subjects With Non-Myeloid Malignancies Receiving Chemotherapy
The purpose of this study is to assess the ability of darbepoetin alfa to maintain hemoglobin concentrations greater than or equal to 10 g/dL when administered every 3 weeks (Q3W).
- Trial name
- NCT00120705
- Testing
- darbepoetin alfa
- Volunteers
- 204 people
- Sponsor
- Amgen
Lymphoma, B-Cell, T-Cell Lymphoma
Safety and Efficacy Study of a Dual PI3K Delta/Gamma Inhibitor in Hematological Malignancies
The objective of this study is to evaluate the safety and efficacy of RP6530, a dual PI3K delta/gamma inhibitor in patients with hematologic malignancies.
- Trial name
- PI3K (NCT02017613)
- Testing
- RP6530
- Where
- 3 sites in France, Italy
- Volunteers
- 35 people
- Sponsor
- Rhizen Pharmaceuticals SA
Chronic Myeloid Leukemia (CML), Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL)
Glivec/Gleevec Pediatric (Age 1 to Less Than 4) PK Study in CML, Ph+ ALL Patients and Other Glivec/Gleevec® Indicated Hematological Disorders.
This study will assess the pharmacokinetics of imatinib in pediatric patients ages 1 to <4 years of age to help develop dosing regimens
- Conditions
- Chronic Myeloid Leukemia (CML), Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL), Other Glivec/Gleevec Indicated Hematological Disorders (HES, CEL, MDS/ MPN)
- Trial name
- NCT01066468
- Testing
- Gleevec/Glivec
- Where
- Russia
- Volunteers
- 3 people
- Sponsor
- Novartis Pharmaceuticals
Thrombocytopaenia
A Three-part Study of Eltrombopag in Thrombocytopenic Subjects With Myelodysplastic Syndromes or Acute Myeloid Leukemia
This was a worldwide, three-part (Part 1: open-label, Part 2: randomized, double-blind, Part 3: extension), multi-center study to evaluate the effect of eltrombopag in subjects with myelodysplastic syndromes (MDS) or acute…
- Trial name
- ASPIRE (NCT01440374)
- Testing
- eltrombopag
- Where
- 120 sites in United States, Argentina and 20 more
- Volunteers
- 162 people
- Sponsor
- Novartis Pharmaceuticals
Anemia
A Study of Darbepoetin Alfa for the Treatment of Anemia in Subjects With a Non-Myeloid Malignancy
The purpose of this study is to compare the efficacy of darbepoetin alfa administered using a front-loading approach with subjects receiving standard weekly dosing in the treatment of anemia in subjects with a non-myeloid…
- Trial name
- NCT00117624
- Testing
- darbepoetin alfa
- Sponsor
- Amgen
Acute Myeloid Leukemia
A Study Assessing tOTX015 in Combination With Azacitidine (AZA) or AZA Single Agent in Patients With Newly-diagnosed Acute Myeloid Leukemia (AML) Not Candidate for Standard Intensive Induction Therapy (SIIT)
This study is designed in its first part (phase Ib) to determine the recommended dose of the OTX015 + Vidaza (azacitidine) combination in newly diagnosed acute myeloid leukemia patients not candidate for standard intensive…
- Trial name
- NCT02303782
- Testing
- OTX015, Vidaza (azacitidine)
- Sponsor
- Oncoethix GmbH, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
B-cell Lymphoma, Chronic Lymphocytic Leukemia
Long-Term Follow-Up of AvenCell Sponsored CAR-T Cell Clinical Trials
The goal of this clinical study is to learn more about the long-term safety, effectiveness and prolonged action of patients who participated in an AvenCell-sponsored clinical trial and received treatment with AvenCell's UniCAR or…
- Conditions
- B-cell Lymphoma, Chronic Lymphocytic Leukemia, Hematologic Malignancy, AML (Acute Myelogenous Leukemia)
- Trial name
- PERSIST (NCT07474051)
- Testing
- UniCAR02-T (IMP) With Targeting Module TM123, UniCAR02-T-pPSMA, Allo-RevCAR01- T with Targeting Module R-TM123
- Where
- 5 sites in Germany
- Volunteers
- 178 people
- Sponsor
- AvenCell Therapeutics, Inc.
Solid Tumor, Colorectal Cancer
Phase 1a/1b Study of Aplitabart (IGM-8444) Alone or in Combination in Participants with Relapsed, Refractory, or Newly Diagnosed Cancers
This study is a first-in-human, Phase 1a/1b, multicenter, open-label study to determine the safety, tolerability, and pharmacokinetics of aplitabart as a single agent and in combination in participants with relapsed and/or…
- Conditions
- Solid Tumor, Colorectal Cancer, Non Hodgkin Lymphoma, Sarcoma
- Trial name
- NCT04553692
- Testing
- Aplitabart (IGM-8444), FOLFIRI, Bevacizumab (and approved biosimilars)
- Where
- 58 sites in United States, Australia and 3 more
- Volunteers
- 272 people
- Sponsor
- IGM Biosciences, Inc.
Acute Myelogenous Leukemia, AML
A Study Evaluating Venetoclax in Combination With Low-Dose Cytarabine in Treatment-Naïve Participants With Acute Myelogenous Leukemia
This study consists of two parts: A Phase 1 dose-escalation part that will evaluate the safety and pharmacokinetic profile of venetoclax in combination with low-dose cytarabine (LDAC), define the maximum tolerated dose (MTD), and…
- Trial name
- NCT02287233
- Testing
- Venetoclax, Cytarabine
- Where
- 9 sites in United States, Australia and 2 more
- Volunteers
- 94 people
- Sponsor
- AbbVie
Acute Myeloid Leukemia, Myeloproliferative Neoplasm
A Study of TAS1553 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia (AML) and Other Myeloid Neoplasms
This is a Phase 1, 2-part, open-label, multicenter, first-in-human (FIH) study to assess the safety, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary clinical activity of TAS1553 administered orally to participants…
- Conditions
- Acute Myeloid Leukemia, Myeloproliferative Neoplasm, Myelodysplastic/Myeloproliferative Neoplasm
- Trial name
- NCT04637009
- Testing
- TAS1553
- Where
- 10 sites in United States, Canada
- Volunteers
- 20 people
- Sponsor
- Astex Pharmaceuticals, Inc.
Tumor Pathway Activations Inhibited by Dovitinib
Dovitinib for Patients With Tumor Pathway Activations Inhibited by Dovitinib
The purpose of this signal seeking study was to determine whether treatment with dovitinib (TKI258) demonstrated sufficient efficacy in select pathway-activated solid tumors and/or hematologic malignancies to warrant further…
- Trial name
- SIGNATURE (NCT01831726)
- Testing
- Dovitinib (TKI258)
- Where
- 49 sites in United States
- Volunteers
- 80 people
- Sponsor
- Novartis Pharmaceuticals
Leukemia, Myeloid, Acute, Leukemia, Lymphocytic, Chronic, B-Cell
A Rollover Study for Continued Study Treatment and Ongoing Safety Monitoring
The purpose of this study is to collect long-term safety data in participants with cancers including acute myeloid leukemia, non-Hodgkin lymphoma, myelodysplastic syndrome, chronic lymphocytic leukemia (type of cancer of the…
- Conditions
- Leukemia, Myeloid, Acute, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Non-Hodgkin, Myelodysplastic Syndromes
- Trial name
- NCT06788509
- Testing
- JNJ-75348780, JNJ-67856633, JNJ-54179060
- Where
- 39 sites in Australia, Belgium and 13 more
- Volunteers
- 120 people
- Sponsor
- Janssen Research & Development, LLC
Acute Lymphocytic Leukemia, Acute Myeloid Leukemia
Infusion of Specially Treated Umbilical Cord Stem Cells After Chemoradiation Treatment for Blood Cancers
This study hopes to show that specially treated umbilical cord cells, called stem cells, can be safely given to a person after they receive chemoradiation therapy or chemotherapy for their illness.
- Conditions
- Acute Lymphocytic Leukemia, Acute Myeloid Leukemia, Myelodysplastic Syndrome, Non-Hodgkin Lymphoma
- Trial name
- NCT00089596
- Testing
- Expansion of umbilical cord stem cells
- Where
- 4 sites in United States
- Volunteers
- 10 people
- Sponsor
- ViaCell